Home › Funds › Bain Capital Life Sciences Investors, LLC › AVIR

Bain Capital Life Sciences Investors, LLC position in AVIR

ATEA PHARMACEUTICALS INC · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 2,075,639 shares of AVIR (ATEA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 0.74% of its reported portfolio and ranking #17 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed AVIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.08M sh
Reported value held$10.81M
Portfolio Weight0.74%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's AVIR position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in AVIR in Q3 2023 at 2,485,638 shares (US$7.5M). The position peaked in Q1 2026 at 2,360,638 shares, worth US$12.7M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 2,075,639 shares valued at US$10.8M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.49M $7.46M New
Q4 2023 2.49M $7.58M Hold
Q1 2024 2.49M $10.04M Hold
Q2 2024 2.49M $8.23M Hold
Q3 2024 2.49M $8.33M Hold
Q4 2024 2.49M $8.33M Hold
Q1 2025 2.49M $7.43M Hold
Q2 2025 2.49M $8.95M Hold
Q3 2025 2.49M $7.21M Hold
Q4 2025 2.49M $8.87M Hold
Q1 2026 2.36M $12.70M Reduce
Q2 2026 2.08M $9.65M Reduce
Q3 2026 2.08M $10.81M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AVIR and 13F data

AVIR (ATEA PHARMACEUTICALS INC) is a Health Care company. 28 other funds we track also report a position in AVIR — the largest reported positions include BML Capital Management, LLC (US$35.2M), TANG CAPITAL MANAGEMENT LLC (US$22.4M), Royal Palms Capital LLC (US$2.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AVIR

All AVIR fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held AVIR?

Bain Capital Life Sciences Investors, LLC has disclosed AVIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in AVIR?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 2.08M shares of AVIR (ATEA PHARMACEUTICALS INC), valued at $10.81M, representing 0.74% of its reported portfolio and ranking #17.

Has Bain Capital Life Sciences Investors, LLC been buying or selling AVIR?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in AVIR. The position peaked in Q1 2026 at 2.36M shares.

Which other funds hold AVIR?

Other major institutional holders of AVIR include BML Capital Management, LLC, TANG CAPITAL MANAGEMENT LLC, Royal Palms Capital LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.